antagomiR-144 (Karolinska Institutet)

N/A

Report date: 2025/01/26 19:13:30

NME

Base Information

Drug NameantagomiR-144 (Karolinska Institutet)

Drug Alias NameGeRP-amiR-144amiR-144 (Karolinska Institute)amiR-144

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisenseSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > microRNA

Mechanisms of ActionNuclear factor erythroid 2-related factor 2 inhibitors

TargetsNuclear factor erythroid 2-related factor 2

Therapy Area/IndicationsAtherosclerosisMetabolic Dysfunction-Associated Steatotic Liver Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySweden

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesKarolinska Institutet

China Registration ClassN/A

Develop Information

Active CompaniesKarolinska Institutet

Inactive CompaniesN/A

Active IndicationsAtherosclerosisMetabolic Dysfunction-Associated Steatotic Liver Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A